AbbVie Inc. / Boehringer Ingelheim GmbH (Risankizumab buyout)
2019 · Asset Purchase · $595M · Complete
Announcement Sentiment
88
Strongly positive
AbbVie paid Boehringer Ingelheim $595M to terminate their risankizumab collaboration, giving AbbVie sole worldwide rights. The buyout occurred just before FDA approval of Skyrizi for plaque psoriasis on April 23, 2019. Post-close outcome: the buyout proved decisively value-accretive. Skyrizi became AbbVie's single largest product, overtaking Humira, with global net revenue of $11,718M in full-year 2024 (AbbVie FY2024 8-K) and approximately $17.5B in full-year 2025 (Q4 2025 earnings), making the $595M one-time payment one of the most accretive rights buyouts of the decade.